TY - JOUR T1 - Computational modelling prediction and clinical validation of impact of benralizumab on airway smooth muscle mass in asthma JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.00930-2019 SP - 1900930 AU - Latifa Chachi AU - Sarah Diver AU - Himanshu Kaul AU - Marlon C. Rebelatto AU - Anmarie Boutrin AU - Patricia Nisa AU - Paul Newbold AU - Christopher Brightling Y1 - 2019/01/01 UR - http://erj.ersjournals.com/content/early/2019/07/31/13993003.00930-2019.abstract N2 - Asthma is a heterogeneous condition characterised by chronic inflammation and airway remodelling. T2-mediated airway inflammation, characterised by IL4, IL5 and IL13, has been the recent focus of pharmacotherapy, with a host of targeted biologic agents now available to clinicians [1]. The anti-IL5R agent, benralizumab, causes depletion of eosinophils and basophils via antibody dependent cell-mediated cytotoxicity (ADCC) in blood; however, the mechanism of action in the tissue is uncertain. Benralizumab has reduced exacerbations and improved lung function in clinical trials.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: L. Chachi has nothing to disclose.Conflict of interest: S. Diver has nothing to disclose.Conflict of interest: H. Kaul reports grants from AirPROM, during the conduct of the study.Conflict of interest: M.C. Rebelatto is an employee of and owns shares in AstraZeneca.Conflict of interest: A. Boutrin is an employee of and holds stock options in AstraZeneca.Conflict of interest: P. Nisa has nothing to disclose.Conflict of interest: P. Newbold is an employee of and owns shares in AstraZeneca.Conflict of interest: C. Brightling reports grants and personal fees for consultancy from GlaxoSmithKline, AstraZeneca/Medimmune, Novartis, Chiesi, Roche/Genentech and Boehringer Inglheim, personal fees for consultancy from Vectura, Theravance, PreP, Gilead, Sanofi/Regeneron, Teva, Gossamer and 4DPharma, grants from Pfizer and Mologic, outside the submitted work. ER -